Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 12 854 / https://doi.org/10.3332/ecancer.2018.854

Short Communication

Nurse-led active surveillance for prostate cancer is safe, effective and associated with high rates of patient satisfaction—results of an audit in the East of England

Introduction: Active surveillance (AS) is an option in the management of men with low-stage, low-risk prostate cancer. These patients, who often require prolonged follow-up, can put a strain on outpatient resources. Nurses are ideally placed to develop advanced roles to help meet this increased demand—a model we have utilised since 2014. We set about to comprehensively evaluate our nurse-led AS (NLAS) programme.

Patients and methods: An audit of patient notes was carried out to assess compliance with trust and national guidelines. A questionnaire was designed to capture patients’ experiences of NLAS. This was piloted and then distributed to all patients in our NLAS programme. A second questionnaire was designed to assess the views of stakeholders within the department.

Results: Compliance with various aspects of local guidelines ranged from 88.8% to 100%. 143 patients are currently in the programme with a mean duration of AS of 37.03 months. 104 questionnaires were returned. Most of the patients were aware of the role of the nurse prior to their visit, and all were happy to meet with a nurse. All of the patients indicated their confidence in the nurse monitoring their prostate-specific antigen. Among those requiring further investigations, 85.3% were happy with the information they received prior to their tests. Overall, 96.2% were either very satisfied or satisfied with NLAS. All stakeholders held positive views about NLAS.

Conclusions: NLAS is safe and effective. Patients and stakeholders alike held positive views of the programme.

Keywords: Nurse-led, active surveillance, prostate cancer

Loading Article Metrics ... Please wait

Related articles

Conference Report: From science to real-life oncology—the ECCO 2018 European Cancer Summit, 7–9 September 2018, Vienna, Austria

Abstract | Full Article | PDF Published: 15 Oct 2018 / https://doi.org/10.3332/ecancer.2018.877

Research: Thromboembolic events in patients with advanced stage non-small cell lung cancer treated with platinum-based chemotherapy: a prospective observational study

Abstract | Full Article | PDF Published: 09 Oct 2018 / https://doi.org/10.3332/ecancer.2018.876

Short Communication: Regorafenib adjusted dose for Chilean patients with chemoresistant metastatic colorectal cancer: a case series

Abstract | Full Article | PDF Published: 02 Oct 2018 / https://doi.org/10.3332/ecancer.2018.875

Review: Clinical decision making in postmastectomy radiotherapy in node negative breast cancer

Abstract | Full Article | PDF Published: 26 Sep 2018 / https://doi.org/10.3332/ecancer.2018.874

Research: What information do cancer patients want and how well are their needs being met?

Abstract | Full Article | PDF Published: 25 Sep 2018 / https://doi.org/10.3332/ecancer.2018.873



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation